Phase I, double-blind, randomized, placebo-controlled study investigating the safety, tolerability and concentrations of the study product KAND145 in healthy volunteers

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503909-11-01

Acronym

KAN0008

Enrollment

Registered

2023-10-20

Start date

2023-10-30

Completion date

Unknown

Last updated

2024-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Finland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026